The merger between Merck & Co., Inc., and Sharp & Dohme in 1953 led to the development of one of the most dominant forces in the UK and Irish pharmaceutical industries. The strength to invest in ground-breaking research quickly led to the discovery of many new drugs that changed the way many potentially life-threatening illnesses were treated.
In 1953, the UK headquarters of Merck Sharp & Dohme opened in Hoddesdon, Hertfordshire. The Company then acquired Thomas Morson & Son Ltd. of Ponders End in Middlesex and, in 1964, a new production facility was opened at Hoddesdon. Later, in 1975, the Development Laboratories were built at Hoddesdon and a manufacturing plant was established in Cramlington, Northumberland.
In 1976 a state-of-the-art manufacturing facility was built in Co. Tipperary and since then over €750 million capital investment as been invested in Ireland. Until the end of 2003 marketing for MSD’s products in Ireland was conducted from the UK subsidiary however this all changed in 2004 with the establishment of Merck Sharp & Dohme Ireland (Human Health) Ltd, also known as MSD Human Health.
|